Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Asma Rabab"'
Autor:
Mike English, Chrysanthi Papoutsi, Chris Paton, Sebastian S Fuller, Michuki Maina, Gulraj Grewal, Asma Rababeh
Publikováno v:
BMJ Global Health, Vol 9, Iss 1 (2024)
Introduction Neonatal mortality remains significant in low-income and middle-income countries (LMICs) with in-hospital mortality rates similar to those following discharge from healthcare facilities. Care continuity interventions have been suggested
Externí odkaz:
https://doaj.org/article/a534f53f66ee4a5d863f11678df15046
Autor:
Aris T. Papageorghiou, George Bugg, Louise Shaw, Zarko Alfirevic, Peter von Dadelszen, Sally Higgins, Tommy Mousa, Andrew Sharp, Andrew C. G. Breeze, Jane Harrold, Silvia Mammarella, Christine Cornforth, Edward D. Johnstone, Anna L. David, Mark A. Turner, Lawrence Impey, Helen Russell, Alastair McKelvey, Dharmintra Pasupathy, Andrea Fenn, Rebecca Spencer, Asma Khalil, Therese Hannon, Abby Rand, Sarah J. Stock, Richard J. Jackson, Philip N. Baker, Louise Webster, Tara J Selman, Umber Agarwal, Louise C. Kenny, Elena Greco, D. Vinayagam, Christos Loannou, Asma Rabab, Shalini Patni, Louise Stephens, Mark D. Kilby, Elaine Willis, David T. Howe, Liona C. Poon, Kelly E Cohen, Joe Aquilina, Geraldine Masson
Publikováno v:
Lancet Child and Adolescent Health
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, M A, Kenny, L C, Baker, P N, Johnstone, E, Khalil, A, von Dadelszen, P, Papageorghiou, A T & Alfirevic, Z 2018, ' Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial ', The Lancet Child & Adolescent Health, vol. 2, no. 2, pp. 93-102 . https://doi.org/10.1016/S2352-4642(17)30173-6
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, M A, Kenny, L C, Baker, P N, Johnstone, E D, Khalil, A, Von Dadelszen, P & Papageorghiou, A T & Alfirevic, Z 2018, ' Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial ', The Lancet Child and Adolescent Health, vol. 2, no. 2, pp. 93-102 . https://doi.org/10.1016/S2352-4642(17)30173-6
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, M A, Kenny, L C, Baker, P N, Johnstone, E, Khalil, A, von Dadelszen, P, Papageorghiou, A T & Alfirevic, Z 2018, ' Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial ', The Lancet Child & Adolescent Health, vol. 2, no. 2, pp. 93-102 . https://doi.org/10.1016/S2352-4642(17)30173-6
Sharp, A, Cornforth, C, Jackson, R, Harrold, J, Turner, M A, Kenny, L C, Baker, P N, Johnstone, E D, Khalil, A, Von Dadelszen, P & Papageorghiou, A T & Alfirevic, Z 2018, ' Maternal sildenafil for severe fetal growth restriction (STRIDER): a multicentre, randomised, placebo-controlled, double-blind trial ', The Lancet Child and Adolescent Health, vol. 2, no. 2, pp. 93-102 . https://doi.org/10.1016/S2352-4642(17)30173-6
Summary Background Severe early-onset fetal growth restriction can lead to a range of adverse outcomes including fetal or neonatal death, neurodisability, and lifelong risks to the health of the affected child. Sildenafil, a phosphodiesterase type 5